Analysis shows diagnostic challenges and therapeutic options for metabolic dysfunction-associated steatotic liver disease in metabolic syndrome, highlighting implications for comorbidities.
The article analyzes current concepts of the pathogenesis, diagnosis, and impact on the prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD) in metabolic syndrome. An overview of current diagnostic potential, non-drug and drug therapy for MASLD is provided, as well as an overview of the impact of therapy for comorbidities on its course.
No takes yet. Share an insight, caveat, or question.
Драпкина et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: